# ADARx Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adarx-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.adarx.com
- Total disclosed funding: $321M
- Latest round: Series C (Aug 2, 2023)
- Investors on record: 17

## About

Based in California, US, and founded in 2019 by Dr. Zhen Li, ADARx Pharmaceuticals, Inc. is a biotechnology company that develops RNA targeting therapeutics for treating diseases including genetic, cardiometabolic, and central nervous system diseases. In August 2023, ADARx Pharmaceuticals, Inc. raised USD 200 million in series C funding co-led by new investors Bain Capital and TCG Crossover Management, with participation from other new investors BlackRock, Commodore Capital, Cormorant Asset Management, HBM Partners, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates, Venrock Healthcare Capital Partners, and Vivo Capital. Returning investors Ascenta Capital, Lilly Asia Ventures, OrbiMed Advisors, and SR One.

ADARx Pharmaceuticals' platform helps discover and develop genetic therapeutics that target and edit single point mutations on RNA transcripts enabling the production of desired proteins for the treatment of diseases with a genetic mutation. The RNA targeting platform includes oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies.

ADARx Pharmaceuticals plans to use the July 2021 Series B funding to advance its proprietary RNA platform technologies for base editing, inhibition, degradation, and delivery as well as transitioning its growing pipeline of research phase products into the clinic including initiation of Phase 1 clinical trial for its lead program.

## Funding rounds

- Series C, Aug 2, 2023, $200M — OrbiMed Advisors, Bain Capital, T Rowe Price, HBM Partners, SR One, Vivo Capital, Invus [DUP], Marshall Wace, Lilly Asia Ventures, BlackRock, Redmile Group, Cormorant Asset Management, Commodore Capital, Venrock Healthcare Capital Partners, TCG Crossover Management, Ascenta Capital
- Series B, Jan 26, 2023, $46M — OrbiMed Advisors, SR One, Lilly Asia Ventures, Sirona Capital, Ascenta Capital
- Series B, Jul 30, 2021, $75M — OrbiMed Advisors, SR One, Lilly Asia Ventures, Sirona Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B, Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B, Series C
- Sirona Capital (https://capitalatlas.ai/funds/sirona-capital) — Series B
- Ascenta Capital (https://capitalatlas.ai/funds/ascenta-capital) — Series B, Series C
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Invus [DUP] — Series C
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series C
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Commodore Capital (https://capitalatlas.ai/funds/commodore-capital) — Series C
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners) — Series C
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series C